GlassScriptPhysician profile
Abbas A Anwar
NPI 1912267691
$4,442.29
in general payments reported to CMS, 2019-2025
23 companies · $617 in 2025
The $617 reported for 2025 was more than what a typical Otolaryngology provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $643 · 2020: $462 · 2021: $776 · 2022: $786 · 2023: $706 · 2024: $451 · 2025: $617.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,775.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,774.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $840.93 | 2019-2023 | Sonopet Iq, Core, Na |
| Regeneron Healthcare Solutions, INC. | $658.21 | 2021-2025 | Dupixent |
| Optinose US, INC. | $551.72 | 2019-2025 | |
| Merz Pharmaceuticals, LLC | $413.08 | 2021-2025 | Xeomin |
| Genzyme Corporation | $396.36 | 2021-2025 | |
| Glaxosmithkline, LLC. | $309.71 | 2022-2025 | Nucala |
| Watermark Medical, INC. | $232.43 | 2021 | |
| Aerin Medical INC. | $184.55 | 2023-2025 | |
| Integra Lifesciences Corporation | $181.91 | 2022-2025 | Integra, Primatrix, Integra Dermal Regeneration Template |
| Smith+Nephew, INC. | $155.70 | 2020-2024 | Stravix, Ent Sinus, Rf20000 |
| Acclarent, INC | $155.59 | 2020-2022 | |
| Merz North America, INC. | $60.44 | 2019-2020 | |
| Medtronic, INC. | $53.45 | 2023 | Propel, Sinuva |
| Hikma Pharmaceuticals USA | $48.22 | 2022-2025 | Ryaltris |
| Intersect Ent, INC. | $42.10 | 2020-2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated | $28.91 | 2025 | |
| Acell, INC. | $26.73 | 2019 | |
| Merck Sharp & Dohme LLC | $26.36 | 2025 | Keytruda |
| Eyevance Pharmaceuticals LLC | $19.94 | 2021 | |
| Cook Medical LLC | $16.19 | 2019 | |
| Glenmark Therapeutics INC. | $14.00 | 2019 | |
| Karl Storz Endoscopy-America | $13.43 | 2019 | |
| Checkpoint Surgical, INC | $12.33 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abbas Anwar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.